Jazz Pharmaceuticals v. Lupin: Epidiolex® Patent Suit Dismissed Without Prejudice
Jazz Pharmaceuticals Research UK Limited filed suit in the District of New Jersey against Lupin Ltd. and nine co-defendants, asserting US11963937B2 covering Epidiolex® (cannabidiol oral solution). Claims against Lupin were dismissed without prejudice by stipulation just 69 days after filing — while the broader multi-defendant action continues.
Jazz and Lupin reach early stipulated exit — broader Epidiolex® battle continues
On July 3, 2024, Jazz Pharmaceuticals Research UK Limited filed suit in the U.S. District Court for the District of New Jersey, Case No. 2:24-cv-07550, asserting infringement of US11963937B2 against a broad coalition of generic pharmaceutical companies — including Apotex, Lupin, Cipla, Taro, Ascent, Invagen, Biophore, API Pharma Tech, and Zenara Pharma. The patent-in-suit covers Epidiolex®, Jazz’s FDA-approved cannabidiol oral solution indicated for rare seizure disorders.
Within 69 days of filing, on September 10, 2024, Jazz and Lupin Ltd. executed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), terminating all claims, counterclaims, and affirmative defenses between those two parties without prejudice and without costs. The dismissal is bilateral — both Jazz’s claims against Lupin and Lupin’s defenses and counterclaims are extinguished as to each other — but expressly carved out all other defendants, leaving the litigation alive against eight remaining parties.
The 69-day timeline from filing to Lupin’s exit is notably rapid for ANDA-type pharmaceutical patent litigation, which typically spans years. The without-prejudice nature of the dismissal means Jazz has preserved its right to reassert US11963937B2 against Lupin, suggesting the resolution may reflect ongoing settlement negotiations, a licensing arrangement, or a consent decree rather than a final commercial resolution — though the public record does not disclose the commercial terms, if any, that prompted the stipulation.
Filing to Dismissed without Prejudice in 69 days
69-day case duration; early resolution against Lupin before substantive merits litigation
Dismissed without prejudice: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal — bilateral and court-filed
A Rule 41(a)(1)(A)(ii) dismissal requires agreement of all parties who have appeared and is filed directly with the court without requiring a judicial order. Here, Jazz and Lupin jointly stipulated to dismiss all claims, counterclaims, and defenses between them. The dismissal is self-executing upon filing, and the court retains jurisdiction only to enforce any underlying agreement — suggesting a potential side arrangement between the parties.
Stipulated — no court order requiredJazz preserves all future rights against Lupin under US11963937B2
A dismissal without prejudice does not extinguish Jazz’s patent rights or its ability to refile against Lupin if commercial circumstances change — for example, if Lupin later launches a generic cannabidiol product. Jazz also avoided any adverse ruling on validity or infringement. The retained court jurisdiction clause is a standard signal that a licensing or consent arrangement may govern the parties’ ongoing relationship, though no terms are public.
Rights preserved — refiling possibleLupin exits without admissions — but faces no preclusion shield
Lupin avoids any infringement or validity finding, and its counterclaims (typically invalidity challenges in ANDA litigation) are also dismissed without prejudice. Critically, Lupin cannot claim issue preclusion or claim preclusion from this outcome — it did not win on the merits. If Jazz refiles, Lupin would need to re-litigate its defenses from scratch. The absence of a prejudice bar cuts both ways.
No admissions — no preclusion barEight defendants remain: Epidiolex® exclusivity fight is far from over
Jazz’s withdrawal of claims against Lupin alone does not resolve the broader Epidiolex® patent enforcement campaign. Eight co-defendants — including Cipla, Taro, Apotex, and Ascent — remain active in the litigation. For the cannabidiol pharmaceutical sector, this signals that Jazz is actively managing its litigation exposure on a defendant-by-defendant basis, consistent with a structured settlement approach seen in complex multi-defendant ANDA cases.
Multi-defendant action ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED | Individual | Specialty pharma IP holding company — holder of US11963937B2 covering Epidiolex®Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Lupin Ltd. — Indian generic pharmaceutical manufacturer with U.S. commercial operationsSearch in Eureka ↗ |
| Co-Defendant | API Pharma Tech, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Biophore Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Invagen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | CIPLA USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Taro Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Ascent Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Cipla Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Zenara Pharma Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Defendant counsel | Melissa Ellen Flax | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Carella Byrne Cecchi Olstein Brody & Agnello, PC | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s language is precise: all claims, counterclaims, and affirmative defenses between Jazz and Lupin are dismissed without prejudice, with no costs to either party. The express carve-out — confirming the dismissal does not affect claims against other defendants — is legally significant in multi-defendant ANDA litigation, as it forecloses any attempt by remaining defendants to invoke the Lupin exit as a collateral estoppel or settlement-value anchor. The retained jurisdiction clause suggests an underlying agreement may exist between the parties, the terms of which are not part of the public record.
US11963937B2 — Cannabidiol oral solution formulation (Epidiolex®)
US11963937B2 (application no. US18/320906) protects a pharmaceutical formulation covering Epidiolex® — the first FDA-approved plant-derived cannabidiol oral solution, indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The patent represents downstream formulation and composition protection for Jazz’s flagship rare-disease neurology asset, building on the original cannabidiol approval landscape with more recently granted claim scope.
Epidiolex® generated substantial revenues for Jazz following its acquisition of GW Pharmaceuticals, making US11963937B2 a commercially critical asset in the company’s IP enforcement strategy. The multi-defendant filing against nine generic companies simultaneously — a hallmark of coordinated Hatch-Waxman litigation — reflects the commercial stakes involved. For generic entrants and competitors developing cannabidiol formulations for neurological indications, this patent represents a key freedom-to-operate hurdle that must be assessed before any ANDA filing or product launch.
Should you run an FTO analysis against US11963937B2?
Any company developing a cannabidiol oral solution — whether as an ANDA filer, a 505(b)(2) applicant, or a branded CBD pharmaceutical product for seizure disorders — should assess US11963937B2 before advancing its product through regulatory pathways. The active multi-defendant litigation and Jazz’s demonstrated willingness to enforce this patent make an FTO analysis a prerequisite for development teams working in the cannabidiol neurological formulation space.
PatSnap Eureka’s FTO Search Agent can map your cannabidiol formulation parameters against the granted claims of US11963937B2, identify relevant prior art that may bear on claim validity, and surface related Jazz portfolio patents that could create overlapping exposure. Eureka’s claim charting and semantic analysis tools let your IP and R&D teams evaluate design-around options and monitor the ongoing multi-defendant litigation for developments that may affect your market entry timeline.
Run a freedom-to-operate analysis on US11963937B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabidiol pharmaceutical patent cases in New Jersey District Court
Explore related Hatch-Waxman ANDA patent infringement cases involving cannabidiol and rare-disease pharmaceutical formulations litigated in New Jersey federal court.
What this case signals for the cannabidiol pharmaceutical IP landscape
Early bilateral exits in multi-defendant ANDA cases rarely occur in a vacuum — they typically signal commercial negotiation activity running parallel to the litigation.
Without-prejudice dismissals in ANDA suits are often settlement proxies
When a branded pharma company dismisses a specific generic defendant without prejudice and without costs in a multi-defendant ANDA action, it consistently signals an off-docket arrangement — such as a consent judgment, a delayed entry licence, or a co-promotion deal. The retained court jurisdiction clause here reinforces this reading. Competitors and investors should monitor for any 180-day exclusivity implications.
Jazz’s carve-out strategy protects litigation leverage against remaining defendants
By expressly stipulating that the Lupin dismissal does not affect claims against other defendants, Jazz prevents any collateral estoppel arguments from the Lupin resolution from being deployed by the eight remaining generic challengers. This is standard ANDA litigation management — early individual resolutions are ring-fenced to preserve maximum leverage in the broader enforcement campaign.
LIMITED v Apotex — key questions answered
The without-prejudice dismissal means Jazz retains full rights to refile patent infringement claims against Lupin under US11963937B2 if Lupin subsequently launches or attempts to launch a generic cannabidiol oral solution. No merits determination was made and no preclusion bar was created. Jazz’s rights under the patent are entirely preserved as against Lupin.
Following the September 10, 2024 stipulated dismissal of Lupin, eight defendants remain active in Case No. 2:24-cv-07550: Apotex Inc., API Pharma Tech LLC, Biophore Pharma Inc., Invagen Pharmaceuticals Inc., CIPLA USA Inc., Taro Pharmaceutical Industries Ltd., Ascent Pharmaceuticals Inc., Cipla Limited, and Zenara Pharma Private Ltd.
The patent asserted in Case No. 2:24-cv-07550 is US11963937B2, filed under application number US18/320906. It covers pharmaceutical formulation aspects of Epidiolex® — Jazz’s FDA-approved cannabidiol oral solution for rare seizure disorders including Lennox-Gastaut syndrome and Dravet syndrome.
The public record does not disclose the commercial terms, if any, underlying the stipulation. In Hatch-Waxman ANDA litigation, bilateral without-prejudice dismissals with no costs typically suggest an off-docket agreement — such as a consent judgment, a delayed-entry licence, or a commercial settlement. The retained court jurisdiction clause in the stipulation is consistent with an underlying arrangement governing the parties’ future conduct, though its terms are not public.
Rule 41(a)(1)(A)(ii) allows a plaintiff to dismiss an action without a court order by filing a stipulation of dismissal signed by all parties who have appeared. In Jazz v. Lupin, this mechanism allowed the parties to jointly terminate all claims between them — including counterclaims and affirmative defenses — without requiring judicial approval. The rule is commonly used in pharmaceutical patent cases to implement negotiated exits from multi-defendant litigation.
PatSnap Eureka searches patents and litigation data to answer instantly.